EN DE

CVS Health Corporation (CVS) Fair Value & Analysis

Healthcare · US · Market cap $133B

CH CVS Health Corporation logo CVS Health Corporation CVS · US
Price$96.22
Fair Value$42.54
Upside-55.8%
Quality65/100
Watch CVS Health Corporation for free, get notified when fair value or trend changes. Watch for free
Healthy Growth
Thin margins · 0.7% net margin
Moderate debt · generates free cash flow
2.59% dividend yield
Mixed vs. peers (6/14)
Narrow moat 33/100
Evidence: High Range $22.86 – $42.54 Share as image

Fair value as of: Jul 12, 2026

From 26 valuation models · updated 26 days ago

Fair value updated Jul 12, 2026, revised from $42.51 to $42.54 (+0.1%) since Jun 24, 2026. Share price −7.8% over the past month.

A solid business, but screening 56% overvalued on our models.

What matters now

  • The price sits above even our optimistic bull case ($42.54). The favourable scenario is already priced in.
  • Solid but not exceptional quality (65/100) and above fair value, neither a clear bargain nor a standout compounder.
  • A fairly wide model range ($22.86 to $42.54) leaves room in how you read the outcome.
Share this valuation: 𝕏 WhatsApp

Price vs Fair Value (5 years)

$110.60 $41.28 Fair Value $42.54 May 2021 Aug 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 12, 2026.

How to read this chart

60‑month range $41.28 – $110.60 · fair‑value band $22.86 – $42.54 · the $96.22 price screens above the $42.54 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Jul 12, 2026.

Full chart & analysis →

Which stocks are undervalued right now? Check free Discover now →

Analysis

CVS Health Corporation (CVS) currently trades at $96.22, while our model-based Fair Value estimate is $42.54, implying the stock looks roughly 55.8% overvalued today. We read business quality at 65/100 (solid quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: high).

Over the trailing twelve months, CVS Health Corporation generated revenue of $406B at a net margin of 0.7%. Revenue grew 6.1% year over year. It earns a return on equity of 3.8%. Net debt stands at $85.1B. Fundamentals as of Jul 12, 2026

Our scenario range runs from $22.86 (bear case) to $42.54 (bull case); at $96.22, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The last reported earnings sit well below what analysts expect (earnings in transition, for example after write-downs or an earnings dip); whether the stock is cheap or expensive hinges on the expected recovery actually arriving. Read the fair value with that caveat. The share trades about 2% below its 52-week high and 69% above its 52-week low, currently above its 200-day average. For context, the median of 10 Healthcare peers we cover trades at 16% fair-value upside, at -56%, CVS screens richer than that median.

Fair Value models

Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.

Model BearBaseBull Evidence
Highest evidence
Growth DCF $36.92 $93.88 $189.64 80
Residual Income $42.27 $41.08 $33.70 76
Rev-Margin DCF $33.88 $88.76 $159.03 74
All 26 models by family
DCF Models
FCF DCF $37.34 $98.90 $204.91 38
Owner Earnings $22.61 $70.71 31
5Y Revenue Exit $33.88 $90.14 $166.26 39
5Y EBITDA Exit $55.80 $134.99 $234.21 41
5Y P/E Exit $15.51 $35.07 38
10Y Revenue Exit $31.88 $85.62 $167.31 36
10Y EBITDA Exit $48.88 $118.34 $223.77 37
10Y P/E Exit $10.28 $31.17 $58.30 35
Earnings-Based
Graham-Dodd $9.42 $42.54 $58.33 54
Lynch FV $11.11 $15.87 $20.63 50
PEG = 1.0 $11.11 $15.87 $20.63 46
EPV $29.02 $40.64 $50.82 59
Dividend Discount
Gordon GGM $24.45 $50.83 $80.63 70
DDM Multi-Stage $24.45 $42.86 $53.34 61
Multiples
P/E Multiple $20.78 $27.71 $34.64 63
P/S Multiple $17.67 $23.56 $29.45 58
P/B Multiple $17.67 $23.56 $29.45 55
EV/EBIT $69.13 $105.76 $142.38 53
EV/EBITDA $73.81 $111.99 $150.18 54
EV/Revenue $33.32 $65.06 $96.81 43
Asset-Based
NCAV (Graham) $29.47 $39.50 $58.95 50
Growth DCF
Growth DCF $36.92 $93.88 $189.64 80
Rev-Margin DCF $33.88 $88.76 $159.03 74
Economic Profit
Residual Income $42.27 $41.08 $33.70 76
ROIC Compounder $29.02 $40.64 $50.82 72
Growth Earnings
Growth-Adj P/E $17.53 $25.05 $32.56 68

Widest divergence: Growth DCF ($88.76) versus Earnings-Based ($15.87). Highest evidence: Growth DCF (80).

Key figures & financial health

Revenue (TTM) $406B
Revenue growth (YoY) +6.1%
Net margin 0.7%
Return on equity 3.8%
Free cash flow $7.8B FY2025
P/E ratio 41.6
More key figures
Operating margin 4.1%
EPS (TTM) $2.28
Dividend yield 2.9%
EPS growth (YoY) +63.1%
Net debt $85.1B FY2025

Figures from reported company fundamentals · as of Jul 12, 2026. TTM = trailing twelve months.

Quality Score breakdown

Overall quality 65/100

Of which business quality 55 · Market factors (momentum, volatility) 82

Profitability 39
Margins and returns on capital today
Quality Growth 51
Are margins and returns improving?
Cashflow 52
Earnings quality: real cash, not paper profit
Fin. Strength 38
Balance sheet, leverage, solvency risk
Investment 90
Disciplined investing over empire-building
Low Volatility 78
Calm price path (market factor)
Momentum 82
Price trend over the last 3–12 months (market factor)
52W Momentum 89
Distance to the 52-week high (market factor)
Net Issuance 85
Buybacks instead of dilution

Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.

About the company

CVS Health Corporation provides health solutions in the United States. The company operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments.

Full company description

CVS Health Corporation provides health solutions in the United States. The company operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services, including medical, pharmacy, dental and behavioral health plans, medical management capabilities, Medicare Advantage and Medicare Supplement plans, PDPS and Medicaid health care management services. It serves employer groups, individuals, college students, part-time and hourly workers, health plans, health care providers, governmental units, government-sponsored plans, labor groups, and expatriates. The Health Services segment offers pharmacy benefit management solutions, including plan design and administration, formulary management, retail pharmacy network management, specialty and mail order pharmacy, clinical, disease management, medical spend management services, pharmacy and other administrative services. It serves employers, insurance companies, unions, government employee groups, health plans, PDPS, Medicaid managed care plans, CMS, plans offered on public health insurance, and other sponsors of health benefit plans. The Pharmacy & Consumer Wellness segment sells prescription and over-the-counter drugs, consumer health and beauty products, personal care products, and other general merchandise products. This segment also distributes prescription drugs; and provides related pharmacy consulting and other ancillary services to care facilities and other care settings. It operates online retail pharmacy websites, retail specialty pharmacy stores, compounding pharmacies and branches for infusion and enteral nutrition services. The company was formerly known as CVS Caremark Corporation and changed its name to CVS Health Corporation in September 2014. CVS Health Corporation was founded in 1963 and is headquartered in Woonsocket, Rhode Island.

Company description, as reported by the company or data provider.

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

CVS Health Corporation reported revenue of $402B in FY2025 versus $292B in FY2021, a compound +8.3%/yr. Reported net income was $1.8B in FY2025, compounding −31.4%/yr from FY2021.

Growth Quality 72/100
Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Latest Revenue (FY 2025)
$402B
Latest YoY
+7.8%
Avg. growth/yr (3Y)
+7.6%
Avg. growth/yr (5Y)
+8.4%
Avg. growth/yr (40Y)
+11.7%
Revenue +8.3%/yr
FY21 $292B
FY22 $322B
FY23 $358B
FY24 $373B
FY25 $402B
Net income −31.4%/yr
FY21 $8.0B
FY22 $4.3B
FY23 $8.3B
FY24 $4.6B
FY25 $1.8B

CVS screens 56% overvalued. Compare with UnitedHealth Group →

Share or link this analysis
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Cite: Fair Value Calculator (2026). "CVS Health Corporation Fair Value". https://www.fairvalue-calculator.com/stock/CVS

Recent news

External third-party headlines (Yahoo Finance, Reuters and others), not an editorial selection.

Peer Group

Healthcare Plans · 15 stocks

How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.

Quality Score 65 · Above median
Fair Value upside −56% · Below median
Return on equity (TTM) 4% · Below median
Return on assets 3% · Below median
Net margin (TTM) 1% · Below median
Operating margin (TTM) 4% · Below median
Revenue growth 6% · Above median
Debt / equity 0.80× · Higher than median

Valuation Multiples vs Healthcare Plans median · lower = cheaper

P/E (TTM) 45.7× · Pricier than median
P/B 1.77× · Cheaper than 75% of peers
P/S (TTM) 0.33× · Cheaper than median
P/FCF 17.0× · Pricier than median
EV/EBITDA 12.0× · Cheaper than median
PEG 0.29× · Cheaper than 75% of peers

Snowflake

Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.

VALUE 0 · sector 39
FUTURE 31 · sector 23
PAST 15 · sector 41
HEALTH 60 · sector 65
DIVIDEND 52 · sector 0

VALUE 0: the price sits above our fair-value range.

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.

Similar stocks

10 more Healthcare Plans stocks, each showing price versus our Fair Value estimate (as of Jul 12, 2026).

Stock Price Fair Value vs Fair Value
UnitedHealth Group UNH $423.38 $292.06 -31%
Elevance Health, Inc ELV $372.85 $431.40 +16%
The Cigna Group CI $304.50 $495.42 +63%
Humana Inc HUM $400.00 $127.61 -68%
Centene Corporation CNC $66.61 $111.96 +68%
Molina Healthcare, Inc MOH $233.31 $199.31 -15%
Oscar Health, Inc OSCR $29.10 $58.20 +100%
Alignment Healthcare, Inc ALHC $20.60 $2.37 -88%
Progyny, Inc PGNY $31.93 $16.44 -49%
Bradsaúde S.A SAUD3 R$15.35 R$20.75 +35%

Compare CVS Health Corporation with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Frequently asked questions

Is CVS Health Corporation (CVS) overvalued or undervalued?
As of Jul 12, 2026, our model estimates a fair value of $42.54 versus a price of $96.22, about −56% (overvalued).
What is the fair value of CVS?
Our model-based fair value for CVS Health Corporation is $42.54 (as of Jul 12, 2026), built from audited fundamentals. The current price is $96.22.
What is the quality score of CVS?
CVS Health Corporation has a Quality Score of 65/100. It combines two groups: business quality (profitability, growth, cash flow, balance-sheet strength) and market factors (price momentum, distance to the 52-week high, volatility). Both subtotals are shown separately in the detail view.
What is the revenue of CVS Health Corporation (CVS)?
CVS Health Corporation reported trailing-twelve-month revenue of about $406B (latest available figure, as of Jul 12, 2026).
What is the net profit margin of CVS?
The net profit margin of CVS Health Corporation is about 0.7%, meaning it keeps roughly 0.7% of revenue as net income. Based on the latest reported figures.
Does CVS Health Corporation pay a dividend?
CVS Health Corporation currently shows a dividend yield of about 2.91% relative to its recent price (as of Jul 12, 2026).

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.

14 days Pro free · no card

Track CVS Health Corporation and try Pro for 14 days

One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.

Zero risk: nothing is ever charged. After 14 days you decide whether to stay.